P

PharmaEssentia U.S.A.

Develops biologics for hematology, oncology, immunology

Senior/Principal Scientist - MPN Biology, Translational Sciences

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeBedford, MA, USANo salary listedIn-person

About the Job

Requirements

  • A Ph.D. in hematology, oncology, immunology, immuno-oncology, or a related discipline is required.
  • Three or more years of experience for Senior Scientist or eight or more years of experience for Principal Scientist in the pharmaceutical or biotechnology industries, including leadership and scientific achievement in myeloproliferative neoplasm research and drug discovery.
  • Expertise in myeloproliferative neoplasm in vivo model design and biomarker discovery, including work with contract research organizations and academic collaborators.
  • Experience with myeloproliferative neoplasm-relevant primary human cellular and tissue-based assays to guide indication selection, biomarker discovery, and mechanism of action.
  • Strong analytical skills and proficiency in pharmacokinetic/pharmacodynamic software such as NONMEM, Phoenix WinNonlin, or R.
  • Communication and presentation skills sufficient to convey complex scientific concepts to diverse audiences.
  • Leadership capabilities including mentoring and developing talent, fostering teamwork, and driving results.

Responsibilities

  • Lead the design, planning, and execution of proof-of-concept and translational studies in healthy and myeloproliferative neoplasm mouse models and primary human cellular and tissue systems.
  • Generate pharmacology and biomarker data packages, including mechanism of action and differentiation from competitor programs, and collaborate with cross-functional teams to align studies with discovery, development, and regulatory goals.
  • Collaborate with the clinical development team to further explore BESREMI in myeloproliferative neoplasm and other hematology areas.
  • Conduct translational studies internally and participate in investigator-initiated trials or company-sponsored clinical trials to maximize the clinical potential of BESREMI.
  • Oversee the analysis, interpretation, and reporting of in vitro and in vivo pharmacology and translational biomarker data, including pharmacokinetic and pharmacodynamic parameters, exposure-response relationships, and safety and tolerability profiles.
  • Provide scientific insights to inform decision-making and optimize study outcomes.
  • Contribute to the development and implementation of clinical pharmacology strategies supporting investigational drugs through early clinical development.
  • Generate scientific rationale for dose selection, formulation optimization, and therapeutic target validation.
  • Work with regulatory affairs to support the preparation and review of investigational new drug applications, new drug applications, and marketing authorization applications.
  • Address regulatory inquiries and provide scientific justifications for study designs, endpoints, and data analyses.
  • Serve as a subject matter expert in myeloproliferative neoplasm pathogenesis, ex vivo and in vivo disease models, translational biomarkers, target biology, and candidate therapeutic mechanism of action.
  • Provide guidance and mentorship to junior scientists, clinicians, and project teams.
  • Contribute to scientific literature through publications, presentations, professional conferences, and working groups.
  • Collaborate with data sciences, biologics, immunology and pharmacology, clinical development, and regulatory affairs teams to integrate pharmacology, translational biomarker, and mechanism of action insights into drug development strategies.

Desired Qualifications

  • Extensive experience in hematological malignancies and associated targets and in vitro and in vivo models.
  • Experience in clinical trial design or clinical operations for company-sponsored or investigator-initiated clinical trials.
  • Experience working with academic collaborators through sponsored research agreements or investigator-initiated trials.

About the Company

PharmaEssentia U.S.A.

Develops biologics for hematology, oncology, immunology

PharmaEssentia USA Corporation develops and commercializes biologic medicines in hematology, oncology, and immunology as part of PharmaEssentia Corporation’s global biopharmaceutical program. Its therapies are biologics—medicines made from living organisms—designed to treat blood disorders, cancers, and immune-related diseases by targeting specific biological pathways. The company differentiates itself through its global footprint and sustained scientific focus, expanding operations across the U.S., Japan, China, and Korea and applying deep scientific expertise to bring new biologics to healthcare systems. The overarching goal is to grow its worldwide presence while delivering new biologic treatments to patients in need.

Company size
51-200
Company stage
IPO
Headquarters
Taipei, Taiwan
Founded
2003

Recently Posted Jobs

Explore more opportunities at PharmaEssentia U.S.A.

See more jobs